hemagglutinin

Overview

Hemagglutinin (HA) is the major surface glycoprotein of influenza viruses and one of the principal antigenic determinants targeted by the host immune system. It mediates attachment of influenza A virus and influenza B virus to host-cell receptors containing N-acetyl-β-neuraminic acid, and it is the dominant target of neutralizing antibody responses elicited by infection and vaccination. Because its surface-exposed regions are under strong immune pressure, hemagglutinin undergoes continual antigenic variation, which contributes to seasonal influenza epidemics and the need for updated influenza vaccine formulations.

Structurally and immunologically, hemagglutinin is a central focus of studies of humoral responses, B-cell epitopes, monoclonal antibody binding, and broadly neutralizing monoclonal antibodies. The hemagglutinin head domain is highly immunodominant but variable, while more conserved regions are of interest for cross-subtype immunity and vaccine design. As a result, hemagglutinin is a major component of conventional influenza vaccine, recombinant vaccine, mRNA vaccine, self-amplifying RNA vaccine, and adjuvanted vaccine strategies, including platforms such as mRNA-1010 and FluMist.

Recent Publications Summary

• A recent analysis of the 2024–25 influenza B virus surge identified an antigenically drifted and reassorted lineage, C.3.1/re, in which a clade C.3 virus reassorted with clade C.5.1 viruses and acquired the D197N substitution in hemagglutinin. This change was reported to restore a putative N-linked glycan predicted to mask a key neutralizing antibody epitope, illustrating how hemagglutinin evolution can alter antibody accessibility and contribute to viral fitness 42328860Jun.

• Computational work on the H3N2 influenza virus focused on B-cell epitopes in hemagglutinin and emphasized that continuous antigenic variation in HA is a major driver of influenza pandemics. This type of analysis is relevant to understanding how hemagglutinin shape-shifts affect antibody recognition and guide epitope-focused vaccine and monoclonal antibody design 42554770Aug.

• A subunit vaccine study for multiple respiratory viruses described codisplaying recombinant hemagglutinin ectodomains from three seasonal influenza strains. This approach highlights the use of HA ectodomains as vaccine antigens to broaden immune coverage across influenza strains while integrating hemagglutinin into a multivalent respiratory-virus vaccine platform 42361166Jun.

• Work on a novel influenza B hemagglutinin aimed to redirect neutralizing antibodies against B/Victoria strains, underscoring that the hemagglutinin protein of influenza B viruses has undergone substantial antigenic evolution and that antibodies elicited by older influenza B viruses may be less effective at neutralization and protection 42105398May.

• A conjugate vaccine technology study used hemagglutinin and neuraminidase constructs from the A/Wisconsin/588/2019 (H1N1) strain to generate the CDP-H1 and CDP-N1 vaccine candidates. The study assessed their immunogenicity in murine models, reflecting continued interest in pairing HA with other influenza antigens to improve vaccine responses 42172691May.

• A self-amplifying RNA vaccine study across seasonal influenza subtypes reported sequence optimization strategies that enhanced hemagglutinin antigen expression and enabled development of mRNA vaccine candidates targeting WHO-recommended strains. This work reinforces hemagglutinin as the core encoded antigen in modern RNA-based influenza vaccine design 42081324May.

• Research on childhood immunological imprinting found that cross-subtype antibodies targeting epitopes in the hemagglutinin head domain are rare because these epitopes are variable between influenza virus subtypes. This finding supports the view that the HA head is immunodominant yet highly strain-specific, shaping the breadth of humoral responses and the potential for broadly neutralizing monoclonal antibodies to target more conserved sites 42049037Apr.

• A study of local B-cell immunity and durable memory after live-attenuated influenza intranasal vaccination in humans noted that seasonal influenza vaccines are most frequently delivered as intramuscular inactivated vaccines, which elicit systemic responses against the immunodominant hemagglutinin head domain. This places hemagglutinin at the center of both systemic and mucosal vaccine-induced immunity, including responses induced by FluMist 42054493Apr.

• An adjuvanted vaccine study reported that BECC adjuvants enhanced immune responses against key antigens, including influenza hemagglutinin, and promoted protective efficacy. This supports the role of adjuvantation in improving the immunogenicity of HA-based vaccine formulations 42218860May.

• A phase 2 evaluation of optimized seasonal influenza mRNA vaccine compositions reported that mRNA-1010 encodes hemagglutinins from WHO-recommended influenza strains and demonstrated safety with enhanced immunogenicity. This further illustrates the centrality of hemagglutinin in contemporary influenza vaccine development and strain selection 42441816Jul.

What Changes, What Holds

1. Glycan masking can restore escape at a drifted influenza B hemagglutinin site
NEW DIRECTION Drifted influenza B hemagglutinin can gain fitness by reacquiring a putative N-linked glycan that shields a neutralizing epitope, showing that recent antigenic change can alter antibody access beyond simple amino-acid drift 42328860Jun. This does not displace the baseline view of HA as an antigenically variable immune target; it adds a concrete mechanism by which reassortment and substitution may help circulating lineages evade humoral control.

2. Epitope mapping sharpens how hemagglutinin variation constrains antibody breadth
METHOD Computational epitope analysis does not change the settled account of HA as a major B-cell target, but it refines how those epitopes are being characterized in H3N2 42554770Aug. Its value is methodological: it supports structure-informed selection of strain-sensitive versus conserved sites for vaccine and monoclonal antibody design, while leaving the core biological role of hemagglutinin unchanged.

3. HA ectodomains remain practical multivalent vaccine antigens
REINFORCES Recombinant hemagglutinin ectodomains continue to function as usable vaccine inputs, extending the baseline claim that HA is a central component of modern influenza vaccine platforms 42361166Jun. The new work mainly reinforces breadth-building strategies rather than revising what HA is. It suggests that multivalent display can be used to widen coverage across seasonal strains, but it does not imply a new role for hemagglutinin.

4. Influenza B hemagglutinin has evolved enough to limit legacy antibody protection
REINFORCES Antibodies elicited by older influenza B exposure may neutralize contemporary B/Victoria strains less effectively, which fits the baseline view that HA is under continuous immune pressure and antigenic variation drives escape 42105398May. The important addition is practical: influenza B HA evolution can undermine older humoral memory, strengthening the case for strain-updated or redirecting immunogen designs rather than challenging the established model.

5. Coupling hemagglutinin with neuraminidase remains a plausible way to improve influenza vaccines
REINFORCES HA-based vaccine constructs paired with neuraminidase do not alter the baseline understanding that hemagglutinin is a principal vaccine antigen; they reinforce it by showing HA remains a core component in combination strategies 42172691May. The entry mainly supports continued exploration of multi-antigen formulations, while leaving unresolved whether adding HA to other constructs meaningfully improves protection over HA-focused designs.

6. Sequence optimization can raise hemagglutinin expression in RNA vaccine platforms
REINFORCES Improved antigen expression from optimized RNA constructs strengthens, rather than revises, the established use of hemagglutinin in mRNA and self-amplifying RNA influenza vaccines 42081324May. The consequence is practical: HA remains the central encoded antigen, and manufacturing or codon-design choices may be important determinants of immunogenicity. Nothing here conflicts with the baseline; it sharpens how HA-based RNA vaccines may be made more effective.

7. Cross-subtype head-domain antibodies are uncommon because the hemagglutinin head is highly variable
REINFORCES Rare cross-subtype antibodies to HA head epitopes fit the settled view that the head is immunodominant but variable 42049037Apr. Rather than revising that framework, the finding tightens it by explaining why breadth from head-directed responses is limited and why conserved sites remain the more plausible route to broadly neutralizing antibodies. The baseline stands; the new work makes its immunological consequences clearer.

8. Seasonal vaccines still focus immunity on the hemagglutinin head domain
REINFORCES Intramuscular inactivated influenza vaccination continues to elicit systemic responses against the immunodominant HA head, which is exactly the baseline expectation for conventional influenza vaccines 42054493Apr. The added point is that mucosal and local memory can also be studied after live-attenuated intranasal vaccination, but that broadens the immunology around HA rather than changing its core role as the principal seasonal vaccine target.

9. Adjuvantation can amplify hemagglutinin-directed vaccine responses
REINFORCES Enhanced immunity to HA with BECC adjuvants strengthens the existing view that hemagglutinin is a key vaccine antigen whose effectiveness can be improved by formulation choices 42218860May. The work does not add a new biological function for HA; it supports a familiar one: HA immunogenicity is modifiable, and adjuvant strategies may raise protective responses without altering the baseline understanding of the antigen itself.

10. Seasonal mRNA influenza vaccines still center on hemagglutinin strain selection
REINFORCES mRNA-1010 encoding WHO-recommended hemagglutinins confirms the baseline statement that HA is the core antigen in contemporary RNA influenza vaccine design 42441816Jul. The contribution is confirmation plus optimization: safety and enhanced immunogenicity support continued strain-based HA selection as the organizing principle for seasonal mRNA vaccines. It does not establish a new role for HA, but it strengthens the current one.

Overview update candidates: 1, 3, 4, 5, 6, 7, 8, 9, 10.